Kiromic Biopharma
General Information | |
Business: |
We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. Our proprietary target discovery engine is called “Diamond.” Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells. Diamond is an artificial intelligence bioinformatic approach that can identify novel surface tumor targets. It uses public and proprietary samples and can expand into the tumor target space. |
Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Employees: | 11 |
Founded: | 2006 |
Contact Information | |
Address | 7707 Fannin, Suite 140, Houston, TX 77054, US |
Phone Number | (832) 968-4888 |
Web Address | http://www.kiromic.com |
View Prospectus: | Kiromic Biopharma |
Financial Information | |
Market Cap | $94.1mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-3.73 mil (last 12 months) |
IPO Profile | |
Symbol | KRBP |
Exchange | NASDAQ |
Shares (millions): | 1.3 |
Price range | $12.00 - $12.00 |
Est. $ Volume | $15.0 mil |
Manager / Joint Managers | ThinkEquity |
CO-Managers | Paulson Investment Company |
Expected To Trade: | 10/16/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |